The adipocyte-derived hormone leptin plays a key role in the regulation of food intake and energy expenditure. Recent studies have suggested that leptin is also involved in the pathogenesis of obesity-associated atherosclerosis and cardiovascular disease. In this study, we investigated the associations of leptin and the soluble leptin receptor (sOb-R) with atherosclerosis in patients with type 2 diabetes. Methods: Three hundred seventeen type 2 diabetic subjects were enrolled in this cross-sectional study. Fasting plasma leptin and sOb-R concentrations were measured by enzyme-linked immunosorbent assays. The intima-media thickness (IMT) of the common carotid artery was measured by ultrasound. Results: The IMT was significantly associated with sOb-R concentrations, age, diabetes duration, serum creatinine (sCre) levels, and systolic blood pressure (SBP), but not with leptin concentrations or the leptin/sOb-R ratio. The concentrations of leptin (r = 0.478, p＜0.001) and the sOb-R (r = −0.404, p＜0.001) and the leptin/sOb-R ratio (r = 0.501, p＜0.001) were strongly correlated with IMT in subjects treated with insulin for glycemic control, but not in those treated with diet alone or oral hypoglycemic agents. Multiple regression analysis, including age, sex, diabetes duration, body mass index, SBP, HbA1c, triglycerides, LDL-cholesterol, sCre, smoking, and insulin therapy, revealed that plasma leptin and the leptin/sOb-R ratio were independently associated with IMT in subjects treated with insulin. Conclusions: Plasma leptin and the leptin/sOb-R ratio are associated with atherosclerosis in patients with type 2 diabetes on insulin therapy, and these associations were independent of obesity and other cardiovascular risk factors. Thromb, 2013; 20:186-194. 
Introduction
Leptin, a 16-kDa peptide hormone produced by adipose tissue, plays a pivotal role in the regulation of body weight. Leptin suppresses feeding behavior and increases energy metabolism by acting on the hypo-thalamus 1) . The receptor for leptin (Ob-R), which is expressed abundantly in the hypothalamus, consists of 6 isoforms, resulting from alternative mRNA splicing and/or proteolytic processing. Of these isoforms, the long-form Ob-R (Ob-Rb) possesses a long intracellular domain that is critical for signal transduction 2) . The secreted form of the leptin receptor, Ob-Re or soluble Ob-R (sOb-R), which contains only an extracellular leptin-binding domain, represents the main leptin-binding activity in the human circulation 3, 4) . The sOb-R suppresses leptin-stimulated Ob-Rb signal transduction in vitro 5, 6) , whereas it acts to delay leptin clearance and stabilize circulating leptin, presumably
Methods

Subjects
Three hundred seventeen subjects with type 2 diabetes, including 187 men and 130 women, were consecutively included from patients attending our Diabetes Center at the Osaka City University Hospital from March 2005 to September 2011. The mean age of the subjects was 62 years old (range 19 to 86 years), and the known duration of their diabetes was 9.5±8.8 (SD) years (range 0 to 44 years). The diagnosis of diabetes was based on the criteria of the Japan Diabetes Society 30) . Both current and past smokers were defined as smokers in the analyses. Eighty-five subjects were treated with dietary therapy alone, 125 with sulfonylureas, 52 with α-glucosidase inhibitors, 74 with biguanides, 12 with insulin secretagogues (glinides), 38 with thiazolidinediones, 64 with insulin, and 20 with a combination of drugs, including sulfonylureas, α-glucosidase inhibitors, biguanides, thiazolidinediones, and glinides. All subjects were categorized into the following 2 groups: subjects treated with and without insulin; these groups were referred to as insulin user and nonuser groups in the analyses. Among insulin users, 44 subjects were treated with insulin alone and 20 with insulin in combination with oral hypoglycemic agents. One hundred and thirteen subjects were treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), and 115 subjects with angiotensin Ⅱ receptor blockers (ARB) or angiotensin-converting enzyme inhibitors (ACEIs). Subjects who met the following criteria were excluded from the present study: those with type 1 diabetes or other types of diabetes, those with renal impairment and/or those who were undergoing chronic dialysis therapy. Serum creatinine 1.1 mg/dL, the upper limit of the normal range in our laboratory, was utilized as the cut-off level for excluding subjects with renal impairment. Written informed consent was obtained from all participants, and the study was approved by the local ethics committee.
Measurement of Carotid Atherosclerosis with the Intima-Media Thickness by Ultrasound
The IMT of the common carotid artery was measured by an ultrasonic phase-locked echo-tracking system, which was equipped with a high-resolution real-time 13-MHz linear scanner (ProSound SSD 6500; Aloka, Tokyo), as previously reported 31, 32) . In brief, the examination included approximately 4 cm of the common carotid artery. This region was scanned bilaterally in the longitudinal and transverse projections. The image was focused on the far wall of the enhancing leptin's biological activities and circulating leptin levels in vivo 4, 6, 7) . In humans, plasma sOb-R levels, which are lower in obese subjects than lean subjects, are inversely correlated to leptin levels and the degree of obesity 4, 8) . In addition, sOb-R levels are inversely associated with metabolic risk factors, such as blood pressure, triglycerides, fasting glucose, and the insulin resistance index, and are positively correlated with HDL-cholesterol, which is independent of obesity [9] [10] [11] [12] . The ratio of plasma leptin to sOb-R (leptin/sOb-R) is more strongly associated with body fat mass than leptin alone, and sOb-R co-elutes exactly with the bound leptin fractions in gel filtration profiles 8) ; therefore, the leptin/sOb-R ratio is regarded as a simple and precise index of the free leptin index 13) . Recently, in vitro and in vivo studies have examined the actions of leptin on the development and progression of atherosclerosis 14) . Leptin has been reported to induce vascular cell proliferation and dysfunction, inflammation, thrombosis, and calcification 14, 15) ; however, there has been controversy regarding the link between leptin and cardiovascular disease in clinical studies. Several case-control studies revealed that plasma leptin levels were an independent predictor of the onset of acute coronary events in the general population 16) and in men with mild hypercholesterolemia 17) , and of recurrent coronary events in patients with coronary heart disease [18] [19] [20] , while others did not [21] [22] [23] . Consensus has not been achieved regarding the association of leptin with the intima-media thickness (IMT) of the carotid artery, which is assessed by ultrasound [24] [25] [26] [27] and which is an established surrogate marker of cardiovascular disease 28) . Furthermore, the clinical implications of plasma sOb-R levels or the free leptin index on atherosclerosis have not yet been elucidated 29) , although they have been reported to be associated with obesity, insulin resistance, and metabolic risk factors [9] [10] [11] . Patients with type 2 diabetes have various risk factors for atherosclerosis and often receive insulin therapy, which may easily induce obesity and hyperinsulinemia and possibly accelerate the atherosclerotic process. To date, few studies have helped to resolve these issues in patients with type 2 diabetes.
Aim
The aim of the present study was to clarify the association of plasma leptin levels, soluble leptin receptor levels, and the ratio of leptin to soluble leptin receptor levels with the IMT of the carotid artery, which was assessed by ultrasound in 317 patients with type 2 diabetes who were being treated with and without insulin in a cross-sectional design. Treated with  and without Insulin  Table 1 shows the clinical characteristics of the insulin users, nonusers, and all of the subjects. The insulin-user group was significantly older, with lower BMI, and a longer duration of diabetes than the insulin-nonuser group. HbA1c in the insulin-user group was significantly higher than in the insulin-nonuser group. There were no significant differences in the frequency of smoking, ACEI or ARB treatment, or statin treatment between the insulin-user and nonuser groups. The IMT of the common carotid arteries of all subjects was 1.027±0.559 mm, with a range of 0.203 to 4.618 mm. The IMT in the insulin-user group was not significantly different from that in the insulinnonuser group (1.069±0.529 mm vs 1.016±0.567 mm group, p = 0.501).
Results
Clinical Characteristics of the Subjects
Plasma Leptin and Soluble Leptin Receptor Levels
Plasma leptin in all subjects was 4.7±4.4 ng/mL (range 0.2 to 32.8). As expected, plasma leptin levels in women were significantly higher than in men (7.3 ±5.1 vs 2.9±2.4 ng/mL, p＜0.05). There were no significant differences in plasma leptin between the insulin-user and nonuser groups (5.0±4.9 vs 4.6±4.2 ng/mL, p = 0.548).
Plasma sOb-R in all subjects was 25.6±8.1 ng/ mL (range 11.6 to 74.1). In contrast to plasma leptin levels, there was no significant difference between men and women (25.5±8.6 vs 25.7±7.4 ng/mL, p=0.424). Furthermore, plasma sOb-R levels in the insulin-user group were significantly higher than in the insulinnonuser group (27.7±11.6 vs 25.0±6.9 ng/mL, p = 0.018). The ratio of leptin to sOb-R (leptin/sOb-R), which is an index of free leptin in the circulation, was not different between the insulin-user and nonuser groups (0.24±0.27 vs 0.20±0.19, p = 0.280).
Association between Plasma Leptin or Soluble Leptin Receptor Levels and IMT
The correlations between the IMT of the common carotid artery and possible clinical risk factors for atherosclerosis were examined by simple regression analysis in all subjects and in the insulin-user and nonuser groups ( Table 2) . As expected, in all subjects, age, duration of diabetes, SBP, and serum creatinine levels were significantly and positively correlated with IMT. Age and HbA1c in the insulin-user group and age, duration of diabetes, BMI, SBP, and fasting plasma insulin in the insulin-nonuser group were significantly correlated with IMT.
artery. The IMT was measured in both carotid arteries at the site of the most advanced atherosclerotic lesion that exhibited the greatest distance between the lumenintimal interface and the media-adventitia interface of the far wall, herein defined as maximum IMT.
Assay of Plasma Leptin and Soluble Leptin Receptor Levels
Plasma leptin and sOb-R levels in the circulation were measured with commercial enzyme-linked immunosorbent assay kits (R&D Systems, Inc., Minneapolis, MN). The minimum detectable levels of leptin and sOb-R were 0.16 ng/mL and 0.057 ng/mL, respectively. The intra-and inter-assay coefficients of variation of leptin and sOb-R were 3.2% and 3.5%, respectively, and 4.9% and 6.7%, respectively 9) .
Physical and Laboratory Measurements
Blood pressure was determined by the conventional cuff method with a mercury sphygmomanometer after the subject had rested for at least 15 min. Blood was drawn after an overnight fast in order to analyze the serum concentrations of glucose, total cholesterol, triglycerides, and HDL-cholesterol by standard laboratory methods. Glycated hemoglobin A1c (%) was assessed as an National Glycohemoglobin Standardization Program equivalent value (%), which was expressed by adding 0.4% to the HbA1c (JDS; %) measured by standard laboratory methods and the previous Japanese standard materials 30) .
Statistics
Statistical analyses were performed with JMP 9 software (SAS Institute, Inc., Cary, NC). All results are expressed as the means±SD, unless otherwise indicated. Student's t -test or χ 2 -test was used appropriately for comparisons between 2 groups. Simple and multiple regression analyses were performed in order to evaluate the relationships between IMT and various clinical parameters and leptin or sOb-R levels. Since plasma leptin, sOb-R and the leptin/sOb-R ratio were not distributed normally, those parameters were logarithmically transformed before regression analyses. In multiple regression analyses, IMT was set as a dependent variable and the plasma levels of leptin, sOb-R, or leptin/sOb-R were set as independent variables after adjusting for possible risk factors [age, sex, duration of diabetes, body mass index (BMI), systolic blood pressure (SBP), HbA1c, serum triglycerides, LDL-cholesterol, creatinine levels, and status of smoking] and treatment with ARB/ACEI, statins, and/or insulin. P＜0.05 was considered significant. found to be a factor contributing to IMT with borderline significance (β=−0.132, p = 0.052), and plasma leptin and the leptin/sOb-R ratio were not (β= 0.070, p = 0.442; β= 0.129, p = 0.160, respectively). In the insulin-user group, plasma leptin and the leptin/ sOb-R ratio were significant contributors to IMT (β= 0.454, p = 0.030; β= 0.503, p = 0.033, respectively). On the other hand, in the insulin-nonuser group, plasma leptin, sOb-R levels, and the leptin/sOb-R ratio were not independent contributors to IMT (β= −0.010, p = 0.924; β=−0.100, p = 0.175; β= 0.043, p = 0.672, respectively).
Discussion
The present study demonstrated a close association of plasma leptin, sOb-R, and the free leptin index or leptin/sOb-R ratio with the IMT of the carotid artery in type 2 diabetic patients treated with insulin. Plasma leptin and the free leptin index were found to In all subjects, only plasma sOb-R showed a weak and significant negative correlation with IMT (r =−0.142, p = 0.012), while plasma leptin and the leptin/sOb-R ratio did not (r = 0.013, p = 0.825; r = 0.050, p = 0.374, respectively). In the insulin-user group, plasma leptin showed a close positive correlation with IMT (r = 0.478, p＜0.001), plasma sOb-R showed a negative correlation (r =−0.404, p＜0.001), and the leptin/sOb-R ratio showed a positive correlation (r = 0.501, p＜0.001) with IMT ( Fig. 1) . However, in the insulin-nonuser group, no significant correlation of plasma leptin, sOb-R or the leptin/sOb-R ratio with IMT was found (r =−0.118, p = 0.060; r = −0.065, p = 0.304; r =−0.089, p = 0.155, respectively) (Fig. 2) .
In order to explore the impact of plasma leptin and/or sOb-R on IMT in all subjects and in the insulin-user and nonuser groups, multiple regression analyses were performed, as described in the Statistics section ( Table 3) . In all subjects, plasma sOb-R was All data are expressed as n, mean±SD. Abbreviations: Duration, known duration of diabetes; BMI, body mass index; SBP, systolic blood pressure; Smoker (%), frequency of ex-and current smokers; ARB/ACEI (%), frequency of subjects treated with angiotensin Ⅱ receptor antagonists or angiotensin-converting enzyme inhibitors; Statins (%), frequency of subjects treated with statins; HOMA-R, insulin resistance index by homeostasis model assessment; FPG, fasting plasma glucose; IRI, fasting plasma insulin levels; sCPR, fasting serum C-peptide levels; TC, HDL, and LDL, total, high-density lipoprotein, and low-density lipoprotein cholesterol levels; TG, triglycerides; sCre, serum creatinine levels; IMT, intima-medial thickness of the common carotid artery; Leptin, plasma leptin levels; sOb-R, plasma soluble leptin receptor levels; Leptin/sOb-R, ratio of plasma leptin to plasma soluble leptin receptor levels.
not exert a significant impact on IMT after adjusting for confounding factors was consistent with the previous findings, despite the various differences in the subjects. Plasma free leptin is measured only by gel-chromatography 8) or specific radioimmunoassay methods 33) , which are not simple, and there are presently no commercial-based assays. The ratio of plasma leptin to sOb-R is regarded as an index of free leptin levels 13) , and it shows a strong association with obesity or the percentage of body fat 8, 10, 13) . In 419 healthy Japanese subjects, the free leptin index showed a positive association with BMI, and the insulin resistance index by homeostasis model assessment and a negative association with HDL-cholesterol and adiponectin 11) . The free leptin index has been shown to be associated with cardiometabolic factors, including age, sex, BMI, waist circumference, triglycerides, and fasting glucose in 362 subjects in a community cohort study 10) . In obese subjects with metabolic syndrome, sOb-R or the free leptin index was also closely correlated with the change in body weight 8, 34) . Although these findings of previous studies suggest the possibility of an association of sOb-R and/or the free leptin index with atherosclerosis, only 1 study showed a non-significant association of serum sOb-R concentrations with coronary artery disease in 543 patients referred for coronary angiograbe independent contributing factors to IMT, as were the classical risk factors in all type 2 diabetic patients treated with insulin. Our findings suggest a novel clinical implication of plasma leptin and sOb-R in the mechanisms underlying the development of atherosclerosis in type 2 diabetic patients.
A few clinical studies have reported an association of plasma leptin and IMT [24] [25] [26] [27] . In 120 healthy subjects with a wide BMI range, the IMT of the common carotid artery was positively associated with plasma leptin in both men and women, and this was independent of classical risk factors; however, the association between IMT and plasma leptin was lost after adjusting for BMI 25) . The range of BMI in their study had a wide distribution (31.2±9.4 for men and 29.4±8.1 for women) and was considerably different from the BMI in our study. In 152 type 2 diabetic patients who were treated with sulfonylureas and/or diet therapy alone, plasma leptin was not significantly correlated with the IMT of the common carotid artery, while the leptin/adiponectin ratio was 26) . The type 2 diabetic subjects in their study were older than those in our study and they did not receive insulin therapy. Plasma leptin did not show a significant association with the carotid IMT in 990 individuals in a community cohort study, although plasma adiponectin did 24) . Our finding that plasma leptin alone did Abbreviations are the same as in Table 1 .
IMT in univariate analysis and contributed to IMT with borderline significance in all type 2 diabetic patients after adjusting for other known risk factors for atherosclerosis by multivariate analyses. The negaphy 29) . Our study first explored the association of sOb-R and the free leptin index with IMT in type 2 diabetic patients. Plasma sOb-R was negatively correlated with increases neointimal thickness in wild-type and ob/ob mice, but has no effect in db/db mice 40) . These experimental studies indicate a direct role of leptin in arterial wall thickening. Thus, our findings may indicate that the leptin/sOb-R ratio, as well as plasma leptin alone, is an useful maker of the proatherogenic effects of leptin on the arterial wall in promoting the thickening of the carotid intima-media complex in human type 2 diabetic subjects.
There were a few limitations of our study. First, our study had a cross-sectional design, and neither a causal relationship between leptin and/or sOb-R and IMT nor the interrelationship of insulin therapy with leptin and/or sOb-R was able to be clarified. Second, our type 2 diabetic patients received various antiatherogenic drug interventions, such as anti-hypertensive drugs and statins, which considerably affect the risk factors and the IMT of the carotid artery. In order to minimize the effects of such treatments, the treatment status by the drugs was adjusted in our multivariate analyses. Third, because records of the insulin regimen and daily insulin dose were not available, we could not draw any conclusion as to why insulin therapy contributed to the close relationship between IMT and leptin or the leptin/sOb-R ratio. Finally, glycemic control in our type 2 diabetic patients was poor at the time of entry into the study because the subjects were consecutively recruited from inpatients who were admitted to our ward for the purpose of retreatment for poor glycemic control. Although it is unknown whether poor glycemic control per se affects leptin and/or sOb-R, it may interfere.
Further studies are required to clarify the potential clinical significance of the leptin/sOb-R ratio and the free leptin index as simple biomarkers in managing atherosclerotic complications in type 2 diabetic patients. Furthermore, future prospective studies are warranted to clarify whether modifications of the tive contribution of plasma sOb-R to IMT, shown for the first time in this study, may agree with previous reports demonstrating an inverse relationship between plasma sOb-R and parameters promoting atherosclerosis, such as obesity, insulin resistance, and metabolic risk factors [9] [10] [11] [12] . Furthermore, in our type 2 diabetic patients with insulin therapy, leptin and the free leptin index surprisingly showed a close correlation with IMT. Both insulin and leptin are well known to promote the proliferation and migration of vascular smooth muscle cells by the mitogen-activated protein kinase (MAPK) pathway 35, 36) ; therefore, our findings may indicate that hyperleptinemia and exogenous therapeutic insulin interact to accelerate atherosclerotic processes in the vascular wall.
Free leptin is supposed to be the bioactive form 4) , and it dominantly contributes to increased circulating leptin in obesity and to its decrease in individuals experiencing weight loss 8, 34) . In human obesity, there is a resistance to the satiety and weight-loss effects of leptin 1) , whereas its other actions, including proatherogenic effects on the vascular vessel wall, immune cells, and sympathetic nerve system, are maintained 37) . In line with this concept of selective leptin resistance, both BMI and IMT were independent and positive contributors to the leptin/sOb-R ratio in our subjects (data not shown). In vitro studies have demonstrated that leptin promotes vascular smooth muscle cell proliferation and migration through the activation of MAPK and phosphatidylinositol-3-kinase 35) , hypertrophy through p38 MAPK activation 38) , and matrix remodeling by matrix metalloproteinase-2 expression 39) . Several animal studies support the involvement of leptin in atherosclerosis. Leptin-deficient ob/ ob and leptin receptor-deficient db/db mice are resistant to neointimal thickening after carotid arterial injury despite severe obesity, diabetes, and hyperlipidemia in these animals 40) . The administration of leptin Abbreviations are the same as in Table 1 . In all type 2 diabetic subjects, leptin, sOb-R, or leptin/sOb-R was set as an independent variable after adjustment for possible risk factors (age, sex, duration of diabetes, BMI, systolic blood pressure, HbA1c, serum triglycerides, LDL-cholesterol, creatinine, and status of smoking) and treatment with ARB/ACEI, statins and/or insulin. In the insulin-user and nonuser groups, they were set after adjustment for the same risk factors as above and for treatment with ARB/ACEI and statins.
leptin/sOb-R ratio through lifestyle modification and/ or pharmacological treatment could result in beneficial effects on the advancement of atherosclerosis and/ or cardiovascular outcomes.
Conclusion
We examined the associations of leptin and soluble leptin receptor with the IMT of the carotid artery in 317 subjects with type 2 diabetes. Plasma leptin and the leptin/sOb-R ratio were independent determinant factors of IMT in patients treated with insulin. These findings suggest that the leptin/sOb-R ratio is a free leptin index and is associated with subclinical atherosclerosis, independently of obesity and other cardiovascular risk factors in type 2 diabetic patients.
